
From cooking to kegels: daily lessons for prostate cancer patients drop care costs
Dr. Gabriela Ilie, soillse scientist in prostate cancer quality of life research at Dalhousie University, second from right, adjusts a Muse device to measure brainwaves while leading a meditation session with prostate cancer patients in Halifax on Friday, Feb. 22, 2019. THE CANADIAN PRESS/Darren Calabrese
HALIFAX — A new study that found a daily dose of information which helps men cope with the physical and mental distress of prostate cancer is also saving Nova Scotia's health system money.
'This is one of those rare interventions that improves outcomes and reduces costs,' wrote Gabriela Ilie, a co-author who is a research psychologist and professor at Dalhousie University's medical faculty, in a recent email about the 'patient empowerment program,' or PEP.
The program created in 2019 by Ilie and radiation oncologist Dr. Rob Rutledge includes pelvic exercises to improve bladder control, aerobic and strength exercise routines, and instruction on how to maintain intimacy despite lost sexual capacity.
The six months of videos — delivered by email — also teaches meditation methods and provides 'mostly plant-based' cooking lessons. Participants may sign up for a 'buddy system' to offer mutual support as men recover from radiation, surgeries and hormone therapies.
The cost-effectiveness study, carried out between 2020 and 2022 and released June 13 in the Canadian Urological Association Journal, concluded that 66 men participating made an average of about 11 visits to seek medical help, versus 16 for the 62 men receiving 'standard care' over a one-year period.
'That's a reduction of about four fewer medical visits per man, a meaningful shift when scaled across the medical system,' wrote Ilie in an email.
Using medical billing data, the researchers said that created a 'direct savings' of about $661 per patient over a year, after taking into account the program's costs. The total billings for participants over the year averaged about $1,195, versus about $1,856 for non-participants, the paper says.
Ilie said the study also observed 'a 31 per cent reduction in... psychological distress at 12 months among the participants.'
Earlier peer-reviewed research on the 'patient empowerment program,' or PEP, has shown improved urinary function and weight loss among the men who followed the video regimes created by Ilie and Rutledge — who are married.
While surgery, radiation and hormone treatments can lead to a cure in prostate cancer treatment, Rutledge and Ilie argue the health system has failed to provide support after diagnosis, even as research shows men often struggle with mental health issues.
Surgery can often damage the nerve ends near the prostate, a walnut-sized gland above the genitals. This injury can limit the ability of men to have erections — which research has indicated often leads to feelings of guilt, loss and inadequacy. Treatments also often lead to having incontinence, increasing social isolation and depression.
To counter this, the PEP videos created by the researchers is a carefully orchestrated routine including text message reminders for the pelvic exercises.
Joseph Lynton, a retired psychotherapist who participated in the study, said he joined on his surgeon's advice after a 'life changing' operation to remove the prostate gland and surrounding tissues.
The 72-year-old said he found himself feeling self-conscious — and at times isolated — due to his incontinence.
Once in the PEP program, Lynton said it helped him gained a 'sense of optimism' as he listened to other participants in zoom calls sharing information and worked 'religiously' at the prescribed pelvic exercises, referred to as kegels, to combat incontinence.
'Losing your prostate can affect a very sensitive and important part of your masculinity ... I would say that I did feel a certain degree of depression and I think being part of the program helped me through that,' he said.
Lynton also said he would have needed further treatments for his mental health without the program. 'When I joined the program, I felt I didn't need that (clinical treatment for anxiety) anymore,' he said.
Rutledge and Ilie spend many of their spare hours working on the videos and have widened their application to pilot projects with other cancer patients.
While the initial concept for the program attracted philanthropic support through the Soillse Research Fund, created by Frank and Debbi Sobey, they say their research is suggesting the 'empowerment' method could be used more widely in the public health system.
They are seeking support from Nova Scotia Health's cancer care division to help fund a larger pilot project, said Rutledge.
Jill Flinn, senior director, of Nova Scotia Health's cancer care program said in an email that the research findings have been reviewed and 'it is clear the program has had and continues to have a positive impact on the lives and well-being of patients with prostate cancer and their families.'
'Their request for cancer care program funding will be reviewed, along with other requests.'
Oncologist Dr. Christopher Booth, a co-chair of an international study on the impact of exercise on recurrence of colon cancer, said in a recent email there's a growing body of evidence that 'simple, cost-effective interventions that are empowering for patients' are improving wellness during treatment.
His group's recently released colon cancer study found that patients who participated in a supervised exercise program after completing their chemotherapy were 28 per cent less likely to have their colon cancer return than patients in the control group.
Booth, who is also a researcher at Queen's University in Kingston, Ont., said health administrations are 'interested in these interventions but current funding streams are still largely aligned around 'traditional' forms of cancer therapy.'
'It will take new thinking and investment in this space,' he said.
This report by The Canadian Press was first published June 25, 2025.
Michael Tutton, The Canadian Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
32 minutes ago
- CTV News
Heat warning issued in Nova Scotia for the second day in a row
Heat warning is in place for the second day in a row for western and central Nova Scotia. Heat warning is in place for the second day in a row for western and central Nova Scotia. Heat warning issued in NS for second day in a row A heat warning remains in effect for most of mainland Nova Scotia for the second day in a row. Environment Canada says the maximum temperature Wednesday will be 30 degrees, though it will feel more like 35 degrees with the humidex. That's a bit cooler than Tuesday, when temperatures felt near 40 degrees with the humidex in western and central Nova Scotia. Environment Canada says conditions will be cooler along the coast. The heat warning is in effect for the following counties: Annapolis Colchester – Truro and south Digby Halifax Hants Kings Lunenburg Queens Shelburne Yarmouth Cooler temperatures are expected Thursday and into the weekend. There are no heat warnings in New Brunswick or P.E.I. 'Heat warnings are issued when very high temperature or humidity conditions are expected to pose an elevated risk of heat illnesses, such as heat stroke or heat exhaustion,' explains Environment Canada in its alert. The agency is urging residents to check on seniors, people who live alone and anyone who is at greater risk of heat-related illness. It's also asking people to watch for early signs of heat exhaustion, which include: headache nausea dizziness thirst dark urine intense fatigue Those symptoms, along with hot, red skin, confusion and a change in consciousness, can indicate signs of a heat stroke, which is a medical emergency. Environment Canada says 911 should be called if heat stroke is suspected. 'While you wait for medical attention, try to cool the person by moving them to a cool place, removing extra clothing, applying cold water or ice packs around the body,' says the agency. 'Drink water often and before you feel thirsty to replace fluids.' As for ways to beat the heat, Environment Canada offers these recommendations: close blinds and shades open windows if it's cooler outside than inside turn on fans and/or air conditioning move to the coolest area of your home go to a cool public space, such as a cooling centre, community centre or library For more Nova Scotia news, visit our dedicated provincial page


CBC
35 minutes ago
- CBC
N.S. won't buy air conditioners for low-income people with health issues
Social Sharing A Nova Scotia woman on income assistance who succeeded in forcing the province to pay for her air conditioner says she's sad other low-income people won't get the same relief. Last October, Julie Leggett from New Glasgow, N.S., won an appeal to receive provincial funding for an air conditioner because of a chronic health condition. But the decision by the income assistance appeal board didn't force the province to cover the cost of air conditioners for other low-income people with health issues. Leggett raised her concerns during the November provincial election campaign, arguing government policy should be changed to help people cope during heat waves. Progressive Conservative Leader Tim Houston, whose party won the election, had said on the campaign trail that he would look into adding air conditioners to a list of special needs covered by the social assistance program. But a spokesperson for the Department of Social Development said on Tuesday that the government was not planning on changing the policy.


Globe and Mail
an hour ago
- Globe and Mail
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
BMY depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. Legacy Portfolio is adversely impacted due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect. Sales of blood thinner medicine Eliquis were down 4% in the first quarter due to the impact of Medicare Part D redesign in the United States. In such a scenario, the performance of new drugs is key to BMY's growth. Thalassemia drug, Reblozyl, has put up a stellar performance, driven by strong growth in the first and second-line treatment of myelodysplastic syndromes (MDS)-associated anemia. The drug should contribute significantly in the coming decade. Revenue growth has been good for the leading immuno-oncology drug Opdivo, driven primarily by volume growth. Sales of CAR T cell therapy, Breyanzi, also continue to gain traction from the approval of new indications and expanded manufacturing capacity. Camzyos has also witnessed strong global uptake in obstructive HCM. BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. Competition for BMY's Key Drugs Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. The immuno-oncology space is dominated by pharma giant Merck 's MRK blockbuster drug Keytruda (pembrolizumab). Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda. Pfizer PFE is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Last month, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. BMY is also trying to develop bispecific antibodies. BMY's Price Performance, Valuation and Estimates Shares of Bristol Myers have lost 15% year to date compared with the industry 's decline of 3.4%. From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY's shares currently trade at 7.34x forward earnings, lower than its mean of 8.54x and the large-cap pharma industry's 14.79X. The Zacks Consensus Estimate for 2025 and 2026 earnings per share has moved south in the past 60 days. BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report